XJun Biotech Wins Two Prestigious Awards at TBI Summit for AI-Driven Probiotic Innovation and Industry Collaboration

On January 16, the 6th TBI Outstanding Brand Innovation Summit concluded in Shanghai, and the much-anticipated list of winners for the TBI Outstanding Brand Innovation Awards was officially announced.

As one of the most influential cross-industry comprehensive authoritative awards in China, the TBI Outstanding Brand Innovation Awards focus on brand growth and innovative value in the digital era. A jury consisting of over a hundred industry experts from Fortune 500 companies, well-known media outlets, leading investors, and marketing service providers conducts rigorous evaluations to identify industry exemplars that combine innovative boldness with practical value.

Xbiome's Dual Awards Reflect Expert and Public Recognition of Its AI+BT-Driven Cutting-Edge Gut Microbiome Technology Transfer Capability, Demonstrating the Jury's Full Endorsement of Xbiome’s New Paradigm for Industry Collaboration Through Probiotics Research, Establishing the Company’s Benchmark Status in the Upstream Probiotics R&D Sector.

Xbiome Honored as "AI Forward-looking Innovative Practice Brand of the Year" for Its Scientific Evidence-based Probiotic Strain Development System Built Over the Years. As a national high-tech enterprise established in 2017, Xbiome has built an industry-leading AI+BT microbiome research and industrial transformation platform, which has been recognized by the Guangdong Provincial Department of Science and Technology as the "Guangdong AI+BT Microecology Engineering Technology Research Center."

Xbiome has assembled a global top-tier scientific team and developed an AI-driven innovative strain screening platform. Utilizing cutting-edge technologies such as whole-genome analysis, AI metabolite prediction, and in vivo and in vitro functional validation, Xbiome efficiently screens star strains from tens of thousands of China-sourced strains and conducts pharmaceutical-grade functional validation and clinical evidence-based research.

Currently, Xbiome has submitted dozens of patents related to its self-developed functional strains, with nine receiving national authorization. The self-developed patented strains XA-1416, XA-2103, and XA-768 have solid scientific evidence-based foundations and data from animal and human trials in areas such as weight management, sleep health, and intestinal care.

Xbiome firmly believes that the value of technological innovation lies in its practical application and contribution to human health. With leading upstream R&D capabilities in probiotic strains, the company has established in-depth collaborations with numerous top food, beverage, and probiotic enterprises both in China and internationally, including Mead Johnson (China), Fonterra, WonderLab, Chayan Yuese, Shu Tree Puff, and Health Express. These partnerships have not only brought Xbiome's self-developed strains to hundreds of millions of consumers but have also repeatedly set benchmark cases for cross-disciplinary collaboration in gut microbiome research.

Dr. Tan Yan, Co-founder and CEO of Xbiome, Awarded "Brand Master of the Year" at TBI Outstanding Brand Innovation Awards. After completing his doctoral studies at Boston University and research work at the Broad Institute, Dr. Tan returned to China to establish Xbiome, formulating a "research-technology commercialization-industrial collaboration" development strategy. He has driven the company’s transformation from a research-driven enterprise to a platform-oriented enterprise, achieving globalized industry-academia-research cooperation. While leading Xbiome in gut microbiome research and innovation, Dr. Tan Yan has gradually emerged as a recognized leader in the microbiome field among industry peers and investors. This accolade highlights the industry's recognition of his innovative vision and contributions.

Xbiome Wins Two TBI Awards, Recognizing Its Scientific Research and Industrial Achievements, and Showcasing Its Brand Influence and Technological Empowerment as a Probiotics R&D Company.Xbiome will continue to focus on AI+BT as its core, build a scientific brand, deeply engage in the innovative R&D of "China-produced bacteria," improve the industry collaboration system, and provide scientifically evidenced, functionally innovative strain and formulation solutions to global and industry-wide partners, jointly promoting the high-quality development of China's probiotics industry.

-End-